Skip to content
Topics
Stories

The J&J rescue mission starts with a choice

People in this story

The Atlantic, May 2021

Had Johnson & Johnson’s COVID-19 vaccine been the first to get the FDA’s green light, it might have been hailed from the get-go for what it actually is: a scientific and technological marvel. It requires just one injection to confer full immunity—a boon for needlephobes and tough-to-reach populations who can’t easily access a second dose. It’s relatively cheap and has forgiving refrigeration requirements, making it a breeze to ship and store. And clinical trials showed that it’s a knockout at guarding against hospitalization and death, and 66 percent effective at preventing moderate to severe cases of COVID-19, even amid the rise of antibody-dodging coronavirus variants. Johnson & Johnson accomplished all this in less than a year, granting the world a safe and effective vaccine crucial to hastening the pandemic’s eventual end.

That’s not how the J&J story played out.

Continue reading at The Atlantic.

More Stories

Funding urban climate justice

06.14.2022

Mass. gun laws ‘help save lives.’ Sen. Ed Markey is, again, asking for the rest of the U.S. to follow suit.

06.08.2022

The next Big Dig shouldn’t be a dig

06.21.22
Op-eds